CDX2 and cancer: With respect to subgroups by different cancer types, a high CDX2 level reflected a favourable 5-year OS for patients with gastric cancer (OR: 0.32, 95%CI: [0.18,0.55], P < 0.0001, I2 = 71%), colorectal cancer (OR: 0.37, 95%CI: [0.25,0.56], P < 0.00001, I2 = 52%) and other cancer types (OR: 0.20, 95%CI: [0.11,0.36], P < 0.00001, I2 = 53%) (Figure 5).